ASCO: Weekly paclitaxel effective as standard-dose regimen in breast CA

Share this content:
ASCO: Fewer Side Effects With Weekly Paclitaxel in Breast CA
ASCO: Fewer Side Effects With Weekly Paclitaxel in Breast CA

MONDAY, June 3 (HealthDay News) -- For women with breast cancer, low-dose weekly paclitaxel is as effective as the standard-dose regimen given every two weeks, with fewer side effects; and axillary radiotherapy (ART) may be better than axillary lymph node dissection (ALND) in the case of positive sentinel lymph node biopsy, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

G. Thomas Budd, M.D., from the Cleveland Clinic, and colleagues randomized patients with node-positive or high-risk node-negative operable breast cancer, who had received chemotherapy, to standard-dose paclitaxel given every two weeks or low-dose weekly paclitaxel, each for 12 weeks. The researchers found that five-year progression-free survival rates were similar for the two regimens (82 and 81 percent, respectively). Adverse events, including allergic reactions, muscle and bone pain, and neurologic toxicity, were more frequent with the every-two-weeks versus the weekly schedule.

Emiel J. Rutgers, M.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues randomized women with early-stage, invasive breast tumors with positive sentinel lymph node biopsy to ALND (744 women) or ART (681 women), and followed them for a median of 6.1 years. The researchers observed no significant differences in five-year overall survival (92.5 to 93.3 percent) or disease-free survival rates (82.6 to 86.9 percent) between the groups. Significantly more patients in the ALND group had lymphedema than in the ART group (40 versus 22 percent in first year; 28 versus 14 percent at five years).

"I am sure these findings will lead to many doctors rethinking their strategy for treating patients who have a positive sentinel lymph node biopsy," Rutgers said in a statement.

The Budd study was funded in part by Amgen.

Abstract - Budd
Abstract - Rutgers
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs